Patient-relevant outcomes associated with generic tamsulosin, levothyroxine and amphetamine in the FDA Adverse Event Reporting System: A pilot study

Sathiya Priya Marimuthu, Geetha Iyer, Jodi Segal, Sonal Singh

Research output: Contribution to journalArticle

Abstract

Aim: Patient-reported outcomes associated with adverse events (AEs) reported with generics have not been evaluated. To map AEs associated with generics to the NIH Patient-reported Outcomes Measurement Information System. Methods: We mapped 381 AEs from 148 case reports of generic tamsulosin, levothyroxine and amphetamine/dextroamphetamine to the physical, mental and social domain of the NIH Patient-Reported Outcomes Measurement Information System after reviewing 1237 case reports in the US FDA's Adverse Event Reporting System (FAERS; 2011-2013). Results: 75%, 76% and 71% reports were classified under the physical domain for tamsulosin, levothyroxine and amphetamine/dextroamphetamine, while 9%, 9% and 18% reports were classified under the mental domain, respectively. Conclusion: FAERS reveals several domains of patient-relevant concerns associated with generic drugs.

Original languageEnglish (US)
Pages (from-to)437-447
Number of pages11
JournalJournal of Comparative Effectiveness Research
Volume6
Issue number5
DOIs
StatePublished - Jul 1 2017

Fingerprint

tamsulosin
Amphetamine
Thyroxine
Dextroamphetamine
Information Systems
Generic Drugs
Patient Reported Outcome Measures

Keywords

  • amphetamine
  • FAERS database
  • levothyroxine
  • patient-relevant outcomes
  • PROMIS outcome
  • tamsulosin

ASJC Scopus subject areas

  • Health Policy

Cite this

Patient-relevant outcomes associated with generic tamsulosin, levothyroxine and amphetamine in the FDA Adverse Event Reporting System : A pilot study. / Marimuthu, Sathiya Priya; Iyer, Geetha; Segal, Jodi; Singh, Sonal.

In: Journal of Comparative Effectiveness Research, Vol. 6, No. 5, 01.07.2017, p. 437-447.

Research output: Contribution to journalArticle

@article{9e6fd4d4005f43d19497ac608c71c74f,
title = "Patient-relevant outcomes associated with generic tamsulosin, levothyroxine and amphetamine in the FDA Adverse Event Reporting System: A pilot study",
abstract = "Aim: Patient-reported outcomes associated with adverse events (AEs) reported with generics have not been evaluated. To map AEs associated with generics to the NIH Patient-reported Outcomes Measurement Information System. Methods: We mapped 381 AEs from 148 case reports of generic tamsulosin, levothyroxine and amphetamine/dextroamphetamine to the physical, mental and social domain of the NIH Patient-Reported Outcomes Measurement Information System after reviewing 1237 case reports in the US FDA's Adverse Event Reporting System (FAERS; 2011-2013). Results: 75{\%}, 76{\%} and 71{\%} reports were classified under the physical domain for tamsulosin, levothyroxine and amphetamine/dextroamphetamine, while 9{\%}, 9{\%} and 18{\%} reports were classified under the mental domain, respectively. Conclusion: FAERS reveals several domains of patient-relevant concerns associated with generic drugs.",
keywords = "amphetamine, FAERS database, levothyroxine, patient-relevant outcomes, PROMIS outcome, tamsulosin",
author = "Marimuthu, {Sathiya Priya} and Geetha Iyer and Jodi Segal and Sonal Singh",
year = "2017",
month = "7",
day = "1",
doi = "10.2217/cer-2017-0006",
language = "English (US)",
volume = "6",
pages = "437--447",
journal = "Journal of Comparative Effectiveness Research",
issn = "2042-6305",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - Patient-relevant outcomes associated with generic tamsulosin, levothyroxine and amphetamine in the FDA Adverse Event Reporting System

T2 - A pilot study

AU - Marimuthu, Sathiya Priya

AU - Iyer, Geetha

AU - Segal, Jodi

AU - Singh, Sonal

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Aim: Patient-reported outcomes associated with adverse events (AEs) reported with generics have not been evaluated. To map AEs associated with generics to the NIH Patient-reported Outcomes Measurement Information System. Methods: We mapped 381 AEs from 148 case reports of generic tamsulosin, levothyroxine and amphetamine/dextroamphetamine to the physical, mental and social domain of the NIH Patient-Reported Outcomes Measurement Information System after reviewing 1237 case reports in the US FDA's Adverse Event Reporting System (FAERS; 2011-2013). Results: 75%, 76% and 71% reports were classified under the physical domain for tamsulosin, levothyroxine and amphetamine/dextroamphetamine, while 9%, 9% and 18% reports were classified under the mental domain, respectively. Conclusion: FAERS reveals several domains of patient-relevant concerns associated with generic drugs.

AB - Aim: Patient-reported outcomes associated with adverse events (AEs) reported with generics have not been evaluated. To map AEs associated with generics to the NIH Patient-reported Outcomes Measurement Information System. Methods: We mapped 381 AEs from 148 case reports of generic tamsulosin, levothyroxine and amphetamine/dextroamphetamine to the physical, mental and social domain of the NIH Patient-Reported Outcomes Measurement Information System after reviewing 1237 case reports in the US FDA's Adverse Event Reporting System (FAERS; 2011-2013). Results: 75%, 76% and 71% reports were classified under the physical domain for tamsulosin, levothyroxine and amphetamine/dextroamphetamine, while 9%, 9% and 18% reports were classified under the mental domain, respectively. Conclusion: FAERS reveals several domains of patient-relevant concerns associated with generic drugs.

KW - amphetamine

KW - FAERS database

KW - levothyroxine

KW - patient-relevant outcomes

KW - PROMIS outcome

KW - tamsulosin

UR - http://www.scopus.com/inward/record.url?scp=85027268220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027268220&partnerID=8YFLogxK

U2 - 10.2217/cer-2017-0006

DO - 10.2217/cer-2017-0006

M3 - Article

C2 - 28686057

AN - SCOPUS:85027268220

VL - 6

SP - 437

EP - 447

JO - Journal of Comparative Effectiveness Research

JF - Journal of Comparative Effectiveness Research

SN - 2042-6305

IS - 5

ER -